SEC 13F Intelligence

KARYOPHARM THERAPEUTICS INC

CUSIP 48576UAA4

Karyopharm Therapeutics Inc has 10 institutional holders in Filings Flow’s 13F database, together reporting 156.79M shares worth $60M as of Q4 2022. The largest reported holders are Affinity Asset Advisors, LLC, Opaleye Management Inc., and Exome Asset Management LLC.

Institutional Holders
10
Q4 2022
Reported Value
$60M
Ticker
unmapped
private placement or foreign
Quarters Tracked
3

Ownership Trend

Institutional holders
Q2 ’21: 15Q2 ’21Q4 ’21: 17Q4 ’21Q4 ’22: 10Q4 ’22filingsflow.com
Total reported value
Q2 ’21: $171MQ2 ’21Q4 ’21: $140MQ4 ’21Q4 ’22: $60MQ4 ’22filingsflow.com

Holders

Manager% of PortfolioValueSharesQuarter
Affinity Asset Advisors, LLC$1.9B AUM1.09%$12M15.25MQ3 2025
Exome Asset Management LLC$193M AUM0.99%$2M2.00MQ3 2025
Opaleye Management Inc.$759M AUM0.65%$5M6.00MQ3 2025
BLB&B Advisors, LLC$2.4B AUM0.00%$60,51075.0KQ3 2025
JPMORGAN CHASE & CO$1.56T AUM0.00%$74,63276.0KQ3 2025

Holdings are reported up to 45 days after quarter end. Share counts are as filed and not adjusted for stock splits.